These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2959889)

  • 21. [Liposomes--carriers of cytostatic preparations].
    Afonin NI; Oksinoĭd OE; Ermakova LN
    Gematol Transfuziol; 1984 Nov; 29(11):43-6. PubMed ID: 6085059
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
    Hong F; Mayhew E
    Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5'-O-Palmitoyl- and 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine--novel lipophilic analogues of 5'-fluoro-2'-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results.
    Schwendener RA; Supersaxo A; Rubas W; Weder HG; Hartmann HR; Schott H; Ziegler A; Hengartner H
    Biochem Biophys Res Commun; 1985 Jan; 126(2):660-6. PubMed ID: 3156589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
    Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
    Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy.
    Schwendener RA; Trüb T; Schott H; Langhals H; Barth RF; Groscurth P; Hengartner H
    Biochim Biophys Acta; 1990 Jul; 1026(1):69-79. PubMed ID: 2378882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM; Mehra T; Hansen C; Chin YC
    Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of 5-fluorodeoxyuridine plus cytosine arabinoside infusions in patients with solid tumors.
    Cummings FJ; Hoovis ML; Calabresi P
    Cancer Treat Rep; 1979 Aug; 63(8):1371-4. PubMed ID: 157808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
    Hashida M; Kojima T; Muranishi S; Sezaki H
    Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
    Mizuno NS; Humphrey EW
    Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
    [No Abstract]   [Full Text] [Related]  

  • 31. Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
    van Borssum Waalkes M; Goris H; Dontje BH; Schwendener RA; Scherphof G; Nijhof W
    Anticancer Drug Des; 1998 Jun; 13(4):291-305. PubMed ID: 9627669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
    Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
    Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of lipophilic prodrugs of mitomycin C entrapped in liposome or O/W emulsion.
    Sasaki H; Takakura Y; Hashida M; Kimura T; Sezaki H
    J Pharmacobiodyn; 1984 Feb; 7(2):120-30. PubMed ID: 6427444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
    Schwendener RA; Schott H
    J Cancer Res Clin Oncol; 1996; 122(12):723-6. PubMed ID: 8954169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
    Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
    J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes.
    Kim S; Kim DJ; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(4):307-10. PubMed ID: 3594716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
    Schott H; Schwendener RA
    Anticancer Drug Des; 1996 Sep; 11(6):451-62. PubMed ID: 8836110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.